| Keywords: |
disease course; review; sorafenib; bevacizumab; drug efficacy; hepatitis c; antineoplastic agents; united states; cancer patient; antineoplastic agent; kidney carcinoma; kidney neoplasms; monoclonal antibody; health care policy; cost control; cost effectiveness analysis; drug cost; health care; health care cost; medicare; economics; drug costs; antibodies, monoclonal; carcinoma, renal cell; pazopanib; health care system; low density lipoprotein cholesterol; axitinib; everolimus; cost-benefit analysis; cost benefit analysis; health care access; trends; drug; generic drug; valsartan; drugs, generic; nivolumab; humans; human; priority journal; biosimilar agent; sacubitril
|
